Original Research

Published on 20 Nov 2024

Cost-effectiveness analysis of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: perspectives from the United States and China

in Drugs Outcomes Research and Policies

Wenwang Lang
Qi Ai
Wenwen Zhang
Qinling Jiang
Yulong He
Ming Ouyang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1461571

649 views

Original Research

Published on 20 Nov 2024

Machine learning models can predict cancer-associated disseminated intravascular coagulation in critically ill colorectal cancer patients

in Drugs Outcomes Research and Policies

Li Qin
Jieling Mao
Min Gao
Jingwen Xie
Zhikun Liang
Xiaoyan Li

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1478342

483 views

Original Research

Published on 20 Nov 2024

A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the FAERS and JADER databases

in Drugs Outcomes Research and Policies

Qian Liu
Zhiwei Cui
Chao Deng
Chao Yang
Tao Shi

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1485190

1,446 views

Original Research

Published on 20 Nov 2024

Optimization of initial dosage of quetiapine in schizophrenic patients: effects of fluvoxamine or duloxetine coadministration

in Drugs Outcomes Research and Policies

Xiao Chen
Yue Zhang
Di Yin
Ying-Wei Jin
Su-Mei He
Chen-Xu Liu
Cun Zhang
Dong-Dong Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1496043

494 views

Systematic Review

Published on 19 Nov 2024

Efficacy and safety of lebrikizumab for the treatment of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis

in Drugs Outcomes Research and Policies

Jinger Lin
Min Luo
Qianwei Zhuo
Nuo Chen
Haosong Zhang
Yue Han

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1429709

860 views

Original Research

Published on 19 Nov 2024

Clinical and non-clinical aspects of reimbursement policy for orphan drugs in selected European countries

in Drugs Outcomes Research and Policies

Szczepan Jakubowski
Przemysław Holko
Rafał Nowak
Marisa Warmuth
Marc Dooms
Outi Salminen
Lucas Cortial
Gisbert W. Selke
Christina Georgi
Einar Magnússon

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1498386

805 views

Policy Brief

Published on 14 Nov 2024

Identifying and overcoming challenges in the EMA’s qualification of novel methodologies: a two-year review

in Drugs Outcomes Research and Policies

Ana Drmić
Riccardo Saccà
Thorsten Vetter
Falk Ehmann

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1470908

491 views

Original Research

Published on 14 Nov 2024

Effectiveness analysis of a pharmacist-led intervention for orthopedic perioperative use of antibiotics: a retrospective cohort study

in Drugs Outcomes Research and Policies

Danwei Wu
Yingxu Li
Jiancun Zhen
Yong Wu
Shuang Ren
Yuan Zhao
Ning Sun
Xuanzi Lin
Liangpeng Lai
Wei Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1365370

457 views

Brief Research Report

Published on 13 Nov 2024

Variation in adherence measures as a function of calculation methods

in Drugs Outcomes Research and Policies

Jeffrey M. Rohay
Jacqueline M. Dunbar-Jacob

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1460327

342 views

Systematic Review

Published on 13 Nov 2024

Predicting adverse drug event using machine learning based on electronic health records: a systematic review and meta-analysis

in Drugs Outcomes Research and Policies

Qiaozhi Hu
Yuxian Chen
Dan Zou
Zhiyao He
Ting Xu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1497397

1,090 views

Original Research

Published on 12 Nov 2024

Drug prescriptions in elderly hospitalized patients with cognitive impairment in the Italian Dementia Friendly Hospital project

in Drugs Outcomes Research and Policies

Stefano Govoni
Alessia Rosi
Stefania Preda
Cristina Lanni
Stefano Cappa
Nicola Allegri

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1474986

412 views

Correction

Published on 11 Nov 2024

Corrigendum: The value of second-line anti-HER2 therapy in metastatic HER-2 positive patients: a cost-effectiveness analysis in China

in Drugs Outcomes Research and Policies

Lu Li
Shilei Yang
Fengqi Fang
Li Tian
Ying He
Jia Li
Yanwei Chen
Deshi Dong

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1519505

446 views

Original Research

Published on 08 Nov 2024

Impact of multifaceted interventions on the knowledge, attitude, and practice of adverse drug reactions reporting among healthcare workers in Vietnam: a comparative intervention study

in Drugs Outcomes Research and Policies

Hong Tham Pham
Minh-Thy Tran Doan
Thuy Dang Thi
Dung Nguyen Tuan
Minh-Hoang Tran
Thao Ngoc Phuong Nguyen

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1420914

408 views

Review

Published on 06 Nov 2024

The roles and patterns of critical care pharmacists: a literature review and practical operation model in China

in Drugs Outcomes Research and Policies

Chunyan Wei
Jinhan He
Jingyi Zhang
Huifang Shan
Aidou Jiang
Ying Liu
Guanghui Chen
Chaoran Xu
Linchao Wang
Xiaofen Shao

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1439145

673 views

Original Research

Published on 06 Nov 2024

Concurrent chemoradiotherapy with S-1 versus platinum in the treatment of locoregionally advanced nasopharyngeal carcinoma: a multicenter, retrospective, propensity score-matched analysis

in Drugs Outcomes Research and Policies

Chenbin Bian
Zhuangzhuang Zheng
Jing Su
Sitong Chang
Huiyuan Yu
Jindian Bao
Qin Zhao
Xin Jiang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1394754

415 views

Review

Published on 06 Nov 2024

Chemical adherence testing in the clinical management of hypertension: a scoping review

in Drugs Outcomes Research and Policies

Louise Rabbitt
James Curneen
Michael Conall Dennedy
Gerard J. Molloy

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1452464

698 views

Navigation group

Articles

Cost-effectiveness analysis of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: perspectives from the United States and China

Machine learning models can predict cancer-associated disseminated intravascular coagulation in critically ill colorectal cancer patients

A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the FAERS and JADER databases

Optimization of initial dosage of quetiapine in schizophrenic patients: effects of fluvoxamine or duloxetine coadministration

Efficacy and safety of lebrikizumab for the treatment of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis

Clinical and non-clinical aspects of reimbursement policy for orphan drugs in selected European countries

Identifying and overcoming challenges in the EMA’s qualification of novel methodologies: a two-year review

Effectiveness analysis of a pharmacist-led intervention for orthopedic perioperative use of antibiotics: a retrospective cohort study

Variation in adherence measures as a function of calculation methods

Predicting adverse drug event using machine learning based on electronic health records: a systematic review and meta-analysis

Drug prescriptions in elderly hospitalized patients with cognitive impairment in the Italian Dementia Friendly Hospital project

Corrigendum: The value of second-line anti-HER2 therapy in metastatic HER-2 positive patients: a cost-effectiveness analysis in China

Impact of multifaceted interventions on the knowledge, attitude, and practice of adverse drug reactions reporting among healthcare workers in Vietnam: a comparative intervention study

The roles and patterns of critical care pharmacists: a literature review and practical operation model in China

Concurrent chemoradiotherapy with S-1 versus platinum in the treatment of locoregionally advanced nasopharyngeal carcinoma: a multicenter, retrospective, propensity score-matched analysis

Chemical adherence testing in the clinical management of hypertension: a scoping review